Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Duchenne Muscular Dystrophy market report explains the definition, types, applications, major countries, and major players of the Duchenne Muscular Dystrophy market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Summit Therapeutics
Wave Life
Bristol-Myers Squibb
BioMarin
Sarepta Therapeutics
ITALFARMACO
Daiichi Sankyo
ReveraGen BioPharma
Genethon
Pfizer
Solid Biosciences
NS Pharma
Santhera Pharmaceuticals
PTC Therapeutics
FibroGen
By Type:
Deflazacort
Prednisone
Others
By End-User:
Male
Female
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Duchenne Muscular Dystrophy Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Duchenne Muscular Dystrophy Outlook to 2028- Original Forecasts
-
2.2 Duchenne Muscular Dystrophy Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Duchenne Muscular Dystrophy Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Duchenne Muscular Dystrophy Market- Recent Developments
-
6.1 Duchenne Muscular Dystrophy Market News and Developments
-
6.2 Duchenne Muscular Dystrophy Market Deals Landscape
7 Duchenne Muscular Dystrophy Raw Materials and Cost Structure Analysis
-
7.1 Duchenne Muscular Dystrophy Key Raw Materials
-
7.2 Duchenne Muscular Dystrophy Price Trend of Key Raw Materials
-
7.3 Duchenne Muscular Dystrophy Key Suppliers of Raw Materials
-
7.4 Duchenne Muscular Dystrophy Market Concentration Rate of Raw Materials
-
7.5 Duchenne Muscular Dystrophy Cost Structure Analysis
-
7.5.1 Duchenne Muscular Dystrophy Raw Materials Analysis
-
7.5.2 Duchenne Muscular Dystrophy Labor Cost Analysis
-
7.5.3 Duchenne Muscular Dystrophy Manufacturing Expenses Analysis
8 Global Duchenne Muscular Dystrophy Import and Export Analysis (Top 10 Countries)
-
8.1 Global Duchenne Muscular Dystrophy Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Duchenne Muscular Dystrophy Export by Region (Top 10 Countries) (2017-2028)
9 Global Duchenne Muscular Dystrophy Market Outlook by Types and Applications to 2022
-
9.1 Global Duchenne Muscular Dystrophy Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Deflazacort Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Prednisone Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Duchenne Muscular Dystrophy Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Male Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Female Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Duchenne Muscular Dystrophy Market Analysis and Outlook till 2022
-
10.1 Global Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.2.2 Canada Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.2.3 Mexico Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.2 UK Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.3 Spain Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.4 Belgium Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.5 France Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.6 Italy Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.7 Denmark Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.8 Finland Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.9 Norway Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.10 Sweden Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.11 Poland Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.12 Russia Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.3.13 Turkey Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.2 Japan Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.3 India Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.4 South Korea Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.5 Pakistan Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.6 Bangladesh Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.7 Indonesia Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.8 Thailand Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.9 Singapore Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.10 Malaysia Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.11 Philippines Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.4.12 Vietnam Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.5.2 Colombia Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.5.3 Chile Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.5.4 Argentina Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.5.5 Venezuela Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.5.6 Peru Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.5.7 Puerto Rico Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.5.8 Ecuador Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.6.2 Kuwait Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.6.3 Oman Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.6.4 Qatar Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.6.5 Saudi Arabia Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.6.6 United Arab Emirates Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.7.2 South Africa Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.7.3 Egypt Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.7.4 Algeria Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Duchenne Muscular Dystrophy Consumption (2017-2022)
-
10.8.2 New Zealand Duchenne Muscular Dystrophy Consumption (2017-2022)
11 Global Duchenne Muscular Dystrophy Competitive Analysis
-
11.1 Summit Therapeutics
-
11.1.1 Summit Therapeutics Company Details
-
11.1.2 Summit Therapeutics Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Summit Therapeutics Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.1.4 Summit Therapeutics Duchenne Muscular Dystrophy Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Wave Life
-
11.2.1 Wave Life Company Details
-
11.2.2 Wave Life Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Wave Life Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.2.4 Wave Life Duchenne Muscular Dystrophy Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Bristol-Myers Squibb
-
11.3.1 Bristol-Myers Squibb Company Details
-
11.3.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.3.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 BioMarin
-
11.4.1 BioMarin Company Details
-
11.4.2 BioMarin Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 BioMarin Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.4.4 BioMarin Duchenne Muscular Dystrophy Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Sarepta Therapeutics
-
11.5.1 Sarepta Therapeutics Company Details
-
11.5.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.5.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 ITALFARMACO
-
11.6.1 ITALFARMACO Company Details
-
11.6.2 ITALFARMACO Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 ITALFARMACO Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.6.4 ITALFARMACO Duchenne Muscular Dystrophy Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Daiichi Sankyo
-
11.7.1 Daiichi Sankyo Company Details
-
11.7.2 Daiichi Sankyo Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Daiichi Sankyo Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.7.4 Daiichi Sankyo Duchenne Muscular Dystrophy Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 ReveraGen BioPharma
-
11.8.1 ReveraGen BioPharma Company Details
-
11.8.2 ReveraGen BioPharma Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 ReveraGen BioPharma Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.8.4 ReveraGen BioPharma Duchenne Muscular Dystrophy Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Genethon
-
11.9.1 Genethon Company Details
-
11.9.2 Genethon Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Genethon Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.9.4 Genethon Duchenne Muscular Dystrophy Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Pfizer
-
11.10.1 Pfizer Company Details
-
11.10.2 Pfizer Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Pfizer Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.10.4 Pfizer Duchenne Muscular Dystrophy Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Solid Biosciences
-
11.11.1 Solid Biosciences Company Details
-
11.11.2 Solid Biosciences Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Solid Biosciences Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.11.4 Solid Biosciences Duchenne Muscular Dystrophy Product Portfolio
-
11.11.5 Recent Research and Development Strategies
-
11.12 NS Pharma
-
11.12.1 NS Pharma Company Details
-
11.12.2 NS Pharma Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.12.3 NS Pharma Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.12.4 NS Pharma Duchenne Muscular Dystrophy Product Portfolio
-
11.12.5 Recent Research and Development Strategies
-
11.13 Santhera Pharmaceuticals
-
11.13.1 Santhera Pharmaceuticals Company Details
-
11.13.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.13.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.13.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
-
11.13.5 Recent Research and Development Strategies
-
11.14 PTC Therapeutics
-
11.14.1 PTC Therapeutics Company Details
-
11.14.2 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.14.3 PTC Therapeutics Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.14.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
-
11.14.5 Recent Research and Development Strategies
-
11.15 FibroGen
-
11.15.1 FibroGen Company Details
-
11.15.2 FibroGen Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
11.15.3 FibroGen Duchenne Muscular Dystrophy Main Business and Markets Served
-
11.15.4 FibroGen Duchenne Muscular Dystrophy Product Portfolio
-
11.15.5 Recent Research and Development Strategies
12 Global Duchenne Muscular Dystrophy Market Outlook by Types and Applications to 2028
-
12.1 Global Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Deflazacort Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Prednisone Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Male Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Female Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Duchenne Muscular Dystrophy Market Analysis and Outlook to 2028
-
13.1 Global Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.2.2 Canada Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.2.3 Mexico Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.2 UK Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.3 Spain Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.4 Belgium Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.5 France Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.6 Italy Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.7 Denmark Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.8 Finland Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.9 Norway Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.10 Sweden Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.11 Poland Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.12 Russia Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.3.13 Turkey Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.2 Japan Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.3 India Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.4 South Korea Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.8 Thailand Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.9 Singapore Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.11 Philippines Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.5.2 Colombia Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.5.3 Chile Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.5.4 Argentina Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.5.6 Peru Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.6.3 Oman Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.6.4 Qatar Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.7.2 South Africa Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.7.3 Egypt Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.7.4 Algeria Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Duchenne Muscular Dystrophy Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Duchenne Muscular Dystrophy
-
Figure of Duchenne Muscular Dystrophy Picture
-
Table Global Duchenne Muscular Dystrophy Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Duchenne Muscular Dystrophy Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Deflazacort Consumption and Growth Rate (2017-2022)
-
Figure Global Prednisone Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Male Consumption and Growth Rate (2017-2022)
-
Figure Global Female Consumption and Growth Rate (2017-2022)
-
Figure Global Duchenne Muscular Dystrophy Consumption by Country (2017-2022)
-
Table North America Duchenne Muscular Dystrophy Consumption by Country (2017-2022)
-
Figure United States Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Canada Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Mexico Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Table Europe Duchenne Muscular Dystrophy Consumption by Country (2017-2022)
-
Figure Germany Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure UK Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Spain Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Belgium Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure France Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Italy Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Denmark Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Finland Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Norway Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Sweden Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Poland Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Russia Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Turkey Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Table APAC Duchenne Muscular Dystrophy Consumption by Country (2017-2022)
-
Figure China Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Japan Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure India Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure South Korea Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Thailand Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Singapore Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Philippines Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Table South America Duchenne Muscular Dystrophy Consumption by Country (2017-2022)
-
Figure Brazil Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Colombia Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Chile Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Argentina Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Peru Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Table GCC Duchenne Muscular Dystrophy Consumption by Country (2017-2022)
-
Figure Bahrain Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Oman Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Qatar Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Table Africa Duchenne Muscular Dystrophy Consumption by Country (2017-2022)
-
Figure Nigeria Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure South Africa Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Egypt Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure Algeria Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Table Oceania Duchenne Muscular Dystrophy Consumption by Country (2017-2022)
-
Figure Australia Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Duchenne Muscular Dystrophy Consumption and Growth Rate (2017-2022)
-
Table Summit Therapeutics Company Details
-
Table Summit Therapeutics Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Summit Therapeutics Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table Summit Therapeutics Duchenne Muscular Dystrophy Product Portfolio
-
Table Wave Life Company Details
-
Table Wave Life Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Wave Life Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table Wave Life Duchenne Muscular Dystrophy Product Portfolio
-
Table Bristol-Myers Squibb Company Details
-
Table Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
-
Table BioMarin Company Details
-
Table BioMarin Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table BioMarin Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table BioMarin Duchenne Muscular Dystrophy Product Portfolio
-
Table Sarepta Therapeutics Company Details
-
Table Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sarepta Therapeutics Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
-
Table ITALFARMACO Company Details
-
Table ITALFARMACO Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table ITALFARMACO Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table ITALFARMACO Duchenne Muscular Dystrophy Product Portfolio
-
Table Daiichi Sankyo Company Details
-
Table Daiichi Sankyo Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Daiichi Sankyo Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table Daiichi Sankyo Duchenne Muscular Dystrophy Product Portfolio
-
Table ReveraGen BioPharma Company Details
-
Table ReveraGen BioPharma Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table ReveraGen BioPharma Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table ReveraGen BioPharma Duchenne Muscular Dystrophy Product Portfolio
-
Table Genethon Company Details
-
Table Genethon Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Genethon Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table Genethon Duchenne Muscular Dystrophy Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table Pfizer Duchenne Muscular Dystrophy Product Portfolio
-
Table Solid Biosciences Company Details
-
Table Solid Biosciences Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Solid Biosciences Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table Solid Biosciences Duchenne Muscular Dystrophy Product Portfolio
-
Table NS Pharma Company Details
-
Table NS Pharma Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table NS Pharma Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table NS Pharma Duchenne Muscular Dystrophy Product Portfolio
-
Table Santhera Pharmaceuticals Company Details
-
Table Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table Santhera Pharmaceuticals Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
-
Table PTC Therapeutics Company Details
-
Table PTC Therapeutics Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table PTC Therapeutics Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
-
Table FibroGen Company Details
-
Table FibroGen Duchenne Muscular Dystrophy Sales, Price, Value and Gross Profit (2017-2022)
-
Table FibroGen Duchenne Muscular Dystrophy Main Business and Markets Served
-
Table FibroGen Duchenne Muscular Dystrophy Product Portfolio
-
Figure Global Deflazacort Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Prednisone Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Male Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Female Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Duchenne Muscular Dystrophy Consumption Forecast by Country (2022-2028)
-
Table North America Duchenne Muscular Dystrophy Consumption Forecast by Country (2022-2028)
-
Figure United States Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Duchenne Muscular Dystrophy Consumption Forecast by Country (2022-2028)
-
Figure Germany Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Duchenne Muscular Dystrophy Consumption Forecast by Country (2022-2028)
-
Figure China Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Duchenne Muscular Dystrophy Consumption Forecast by Country (2022-2028)
-
Figure Brazil Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Duchenne Muscular Dystrophy Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Duchenne Muscular Dystrophy Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Duchenne Muscular Dystrophy Consumption Forecast by Country (2022-2028)
-
Figure Australia Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Duchenne Muscular Dystrophy Consumption Forecast and Growth Rate (2022-2028)
-
